Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Organogenesis Holdings (NASDAQ: ORGO) reported Q2 2025 financial results showing a decline in performance. The company posted net product revenue of $100.8 million, down 23% from $130.2 million in Q2 2024. The Advanced Wound Care segment saw a 25% decrease to $92.7 million, while Surgical & Sports Medicine revenue increased 16% to $8.1 million.
The company reported a net loss of $9.4 million ($0.10 per share), an improvement from a $17.0 million loss in Q2 2024. Adjusted EBITDA turned negative at $(3.6) million, compared to positive $15.6 million in the prior year. The company maintained a strong balance sheet with $73.7 million in cash and no debt.
For full-year 2025, Organogenesis updated guidance, projecting revenue between $480-$510 million, representing flat to 6% growth, with net income ranging from $(6.4) million to $16.4 million.
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its second quarter fiscal year 2025 earnings release for August 7, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update. Investors can join via webcast or teleconference using the number 800-715-9871 (646-307-1963 for international) with access code 634899. The webcast will be available on the company's investor relations website for approximately one year.
Organogenesis (Nasdaq: ORGO), a regenerative medicine company, has expressed support for the Centers for Medicare & Medicaid Services' (CMS) proposed new payment methodology for skin substitutes in CY 2026. The proposal introduces a per centimeter square payment system based on FDA classification across both physician office and hospital outpatient settings.
CEO Gary S. Gillheeney highlighted that the new structure aims to reduce system abuse and Medicare spending while ensuring consistent payment across care sites. The proposal notably recognizes PMA products' clinical differentiation and seeks to expand access to innovative wound healing technologies that help reduce amputations and complications.
Organogenesis Holdings (Nasdaq: ORGO) supports the U.S. Centers for Medicare & Medicaid Services' (CMS) decision to delay the implementation of local coverage determinations (LCDs) for skin substitute grafts and cellular tissue-based products (CTP) used in treating diabetic foot ulcers and venous leg ulcers.
The company endorses CMS's move to review coverage policies ensuring patient access to products with high-quality effectiveness evidence, including real-world evidence. CEO Gary S. Gillheeney Sr. recommends CMS implement an integrated coverage and payment policy to address rising Medicare costs while maintaining cost-effective patient care and innovation.
As a four-decade leader in regenerative medicine, Organogenesis pioneers bioengineered living cell products and manufactures advanced wound care therapies, with multiple technology platforms supporting clinically proven solutions that improve outcomes while reducing overall care costs.
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
Management will conduct a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update, followed by a Q&A session. The event will be accessible via webcast through the company's investor relations website, where it will remain archived for approximately one year.
Organogenesis Holdings (NASDAQ: ORGO) reported strong Q4 2024 financial results with net revenue of $126.7 million, up 27% from Q4 2023. The company achieved Q4 net income of $7.7 million compared to a net loss of $0.6 million in Q4 2023.
For full-year 2024, revenue reached $482.0 million, an 11% increase from 2023, driven by Advanced Wound Care products (+12% to $453.6M) and Surgical & Sports Medicine products (+3% to $28.4M). The company ended 2024 with $136.2 million in cash and no outstanding debt.
For 2025 guidance, Organogenesis expects:
- Net revenue between $480.0-$535.0 million
- Net income between $9.5-$38.8 million
- Adjusted EBITDA between $43.6-$83.2 million
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on February 27th, 2025.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly and annual results, provide a corporate update, and conduct a Q&A session. The event will be accessible via live webcast through the company's investor relations website, where it will remain archived for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO) announced plans to expand its manufacturing capacity through a long-term lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. The regenerative medicine company, which focuses on Advanced Wound Care and Surgical and Sports Medicine markets, will maintain its existing operations across multiple locations including Massachusetts, Alabama, California, Florida, and Switzerland. The Rhode Island expansion is subject to state and local tax incentives.
Organogenesis Holdings (Nasdaq: ORGO) welcomes the U.S. Centers for Medicare & Medicaid Services' decision on local coverage determination (LCD) for skin substitute grafts and cellular tissue-based products treating diabetic foot ulcers and venous leg ulcers. The LCD, effective February 12, 2025, is based on peer-reviewed clinical efficacy data. Organogenesis offers 4 products for diabetic foot ulcers, including NuShield, and 2 for venous leg ulcers. The company's NuShield product has been added to the list of covered products, marking a positive development for both the company and industry.